Roche pens death notice for NewLink IDO/TDO cancer collaboration

Just a few weeks out from ASCO, and with more than a touch of inevitability, Roche is axing its IDO/TDO inhibitor work “in its entirety” with partner NewLink Genetics as the fallout from a string of weak IDO trials across biopharma continues.